Equities Analysts Issue Forecasts for KYTX FY2025 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Investment analysts at William Blair lifted their FY2025 earnings estimates for Kyverna Therapeutics in a research report issued to clients and investors on Thursday, November 13th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($3.74) for the year, up from their prior estimate of ($4.04). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. William Blair also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.92) EPS and FY2026 earnings at ($3.60) EPS.

Several other analysts have also issued reports on the company. HC Wainwright boosted their price target on Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Tuesday, November 11th. Finally, Wells Fargo & Company boosted their price objective on Kyverna Therapeutics from $27.00 to $31.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Kyverna Therapeutics Price Performance

Shares of KYTX stock opened at $7.16 on Monday. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $8.45. The firm has a fifty day moving average price of $6.27 and a 200-day moving average price of $4.28. The company has a market cap of $313.61 million, a price-to-earnings ratio of -1.92 and a beta of 3.78.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.12.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Insight Holdings Group LLC grew its holdings in Kyverna Therapeutics by 8.3% during the 1st quarter. Insight Holdings Group LLC now owns 989,054 shares of the company’s stock valued at $1,909,000 after buying an additional 76,139 shares in the last quarter. TD Asset Management Inc lifted its holdings in shares of Kyverna Therapeutics by 179.5% in the second quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock worth $774,000 after buying an additional 161,954 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Kyverna Therapeutics by 22.2% during the first quarter. Bank of New York Mellon Corp now owns 48,784 shares of the company’s stock worth $94,000 after acquiring an additional 8,851 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Kyverna Therapeutics during the second quarter valued at $129,000. Finally, Ethic Inc. purchased a new position in Kyverna Therapeutics during the second quarter valued at $56,000. Institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.